https://www.otcmarkets.com/filing/html?id=17045683

New Post Public Reply Private Reply Replies (0) Message Board
microcaps
447
https://www.otcmarkets.com/filing/html?id=170...WUD04t3dth


New Megiddo Valleys License 434 (“NMVL 434”)

The New Megiddo License 428 (“NML 428”) was initially awarded on December 3, 2020 for a six-month term and was extended several times before expiring on February 1, 2023. Zion Oil & Gas, Inc. filed an amended application with the Israel Ministry of Energy for a new exploratory license on January 24, 2023 covering the same area as its License No. 428, which expired on February 1, 2023. However, its original application to replace License No. 428 was filed on May 11, 2022, and a revised application was filed on August 29, 2022.

On September 14, 2023, the Israel Ministry of Energy approved a new Megiddo Valleys License 434 (“NMVL 434”), allowing for oil and gas exploration on approximately 75,000 acres or 302 square kilometers. This Exploration License 434 will be valid for three years until September 13, 2026 with four 1-year extensions for a total of seven years until September 13, 2030. This NMVL 434 effectively supersedes our previous NML 428.

We continue our exploration focus here based on our studies as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential.

Zion is deploying new technologies, focusing on new stimulation methods for MJ-01, and aiming to potentially unlock hydrocarbon flows in several identified key zones. Zion has already procured service contractors and ancillary items required for efficient operations. Zion must receive approval of its work plan from the Ministry of Energy prior to commencing its re-completion activities. Zion’s planned activities are currently suspended as a result of the Israel-Hamas war (See Subsequent Events for further insight).


from p.34
Note 7 - Subsequent Events

(i) On October 7, 2023, Hamas, a militant terrorist organization in Gaza, infiltrated southern Israel, killing and injuring at least one thousand Israeli citizens. This unprovoked attack led the nation of Israel to declare war on Hamas approximately one week later. As of the date of this report, Israel remains at war, which lead the Company to temporarily discontinue its exploration activities. It is currently not determinable when the resumption of our exploration activities will begin.


(ii) Approximately $391,000 was collected through the Company’s DSPP program during the period October 1 through November 7, 2023.


currently no legal actions-ITEM 1. LEGAL PROCEEDINGS

Securities and Exchange Commission (“SEC”) Investigation
As previously disclosed by the Company, on June 21, 2018, the Fort Worth Regional Office of the SEC informed Zion that it was conducting a formal, non-public investigation and asked that we provide certain information and documents in connection with its investigation, which we did.

On April 5, 2023, the Company received from the Fort Worth Regional Office of the SEC written notice to the Company concluding the investigation as to the Company and that the SEC does “not intend to recommend an enforcement action by the Commission against Zion.”

Litigation

From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes.

The Company is not subject to any litigation at the present time.

Zion Oil & Gas, Inc. (ZNOG) Stock Research Links

ZNOG Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 0

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 128

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 81

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 158

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 30

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 82

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 119

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 18

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading

Top 5 Most Recently Viewed Articles

Immuron Advances IMM-529 Development Following FDA Feedback

Updated Category News Views 289

Immuron Charts Path for Phase 2 Trial of IMM-529 Key Highlights Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI). Previous clinical trials highlight the necessity for ongoing development of IMM-529. The company plans to submit an IND application for IMM-529 in the first half of 2025.

Continue Reading
Enefit Green to Host Webinars for Unveiling 2024 Results

Updated Category News Views 123

Join Enefit Green's Upcoming Webinars on 2024 Results Enefit Green is set to announce its Q4 and annual unaudited results for 2024. The special reveal will occur shortly after the publication of the report, allowing shareholders and investors to gain critical insights into the company's financial standing. Webinar Schedule and Details The webinars will be hosted on the...

Continue Reading
Intapp's Encouraging Earnings Fuel Stock Surge Amid Market Momentum

Updated Category News Views 197

Intapp's Strong Earnings Report Captivates Investors On a positive note for investors, U.S. stocks saw an uplifting day, with the Dow Jones index climbing approximately 250 points. The highlight of the day was the impressive performance of Intapp, Inc. Shares of Intapp, Inc. (NASDAQ: INTA) experienced a sharp increase following the company's announcement of...

Continue Reading
NewAmsterdam Pharma's Upcoming Conference Participation for 2024

Updated Category News Views 229

NewAmsterdam Pharma Announces Conference Participation NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in...

Continue Reading
John Hancock Funds Announce Monthly Distribution Updates

Updated Category News Views 366

Monthly Distribution Announcements from John Hancock Funds John Hancock has announced important updates regarding the distributions for its closed-end funds. These monthly distributions aim to provide returns to investors, ensuring they receive value from their investments in a timely manner. Details of the Monthly Distribution Declaration Key Dates Recently, the board of...

Continue Reading